thymus extract is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
All high schools operate on an alternating A/B-day block scheduling system, where one group of classes are taken on "A-Days" and a different group of classes are taken on "B-Days," and the cycle repeats. Most high schools have between three and four lunch shifts, depending on enrollment and eating accommodations. The only exceptions are Eleanor Roosevelt High School — which has adopted a modified hybrid block schedule in which both traditional single period courses and double period (block schedule) courses are integrated — and the Academy of Health Science at Prince George's Community College.
A pocket watch is a watch that is made to be carried in a pocket, as opposed to a wristwatch, which is strapped to the wrist. They were the most common type of watch from their development in the 16th century until wristwatches became popular after World War I during which a transitional design, trench watches, were used by the military. Watches were also mounted on a short leather strap or fob, when a long chain would have been cumbersome or likely to catch on things. This fob could also provide a protective flap over their face and crystal. Women's watches were normally of this form, with a watch fob that was more decorative than protective. Pocket watches generally have an attached chain to allow them to be secured to a waistcoat, lapel, or belt loop, and to prevent them from being dropped. Chains were frequently decorated with a silver or enamel pendant, often carrying the arms of some club or society, which by association also became known as a fob. Ostensibly practical gadgets such as a watch winding key, vesta case, seal, and/or a cigar cutter also appeared on watch chains, although usually in an overly decorated style. Also common are fasteners designed to be put through a buttonhole and worn in a jacket or waistcoat, this sort being frequently associated with and named after train conductors. An early reference to the pocket watch is in a letter in November 1462 from the Italian clockmaker Bartholomew Manfredi to the Marchese di Mantova Federico Gonzaga, where he offers him a "pocket clock" better than that belonging to the Duke of Modena.
== Awards and recognition == Pfizer has received various awards and recognitions related to its workplace policies and corporate practices. In the United States, Pfizer earned a 100% score from the Human Rights Campaign (2025) on the Corporate Equality Index for LGBTQ workplace equality and ranked highly in the Hispanic Association on Corporate Responsibility (2024) Corporate Inclusion Index. Pfizer was named a "Best Place to Work for Disability Inclusion" in the Disability Equality Index (2024) and received awards such as Top Diverse Employer, Top Hispanic Employer, and Top Disability-Friendly Company by DiversityComm, Inc. (2024). Other recognitions include being named one of "America's Greatest Workplaces" by Newsweek (2023), Clinical Trials Arena Excellence Awards 2023, inclusion in the top 10 of the "World's Most Admired Companies" by Fortune (2023), and being listed as a Top Employer for Diversity and Best Employer for Women by Forbes (2022). Pfizer was also recognized as a "Best Place to Work" by Glassdoor (2021) and a Top Employer by Science (2021) for its practices during the pandemic.
Side effects are generally similar to other antipsychotics. The drug has a relatively well tolerated side effect profile, with low propensity for QTc interval changes, weight gain and lipid-related adverse effects. In a 2013 meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs, it was found to produce the second least (after haloperidol) weight gain, the least QT interval prolongation, the fourth most extrapyramidal side effects (after haloperidol, zotepine and chlorpromazine), and the sixth least sedation (after paliperidone, sertindole, amisulpride, iloperidone and aripiprazole). As with other atypical neuroleptics, lurasidone should be used with caution in the elderly because it puts them at an increased risk for a stroke or transient ischemic attack; however, these risks are not likely to be greater than those associated with antipsychotics of other classes. Similarly, lurasidone should not be used to treat dementia-related psychosis, as evidence has shown increased mortality with antipsychotic use. Weight gain is reported in up to 15 and 16 percent of users. Other possible side effects include vomiting, akathisia, dystonia, parkinsonism, somnolence, dizziness, sedation and nausea.
== Functions == Anabolic processes build organs and tissues. These processes produce growth and differentiation of cells and increase in body size, a process that involves synthesis of complex molecules. Examples of anabolic processes include the growth and mineralization of bone and increases in muscle mass.
Sources: en.wikipedia.org
According to a 2013 Foreign Policy magazine article, NSA's Tailored Access Operations (TAO) unit "has successfully penetrated Chinese computer and telecommunications systems for almost 15 years, generating some of the best and most reliable intelligence information about what is going on inside the People's Republic of China." In 2014, Barack Obama ordered an intensification of cyberwarfare against North Korea's missile program for sabotaging test launches in their opening seconds. On 24 November 2014, Sony Pictures Entertainment hack was a release of confidential data belonging to Sony Pictures Entertainment (SPE). In 2016 President Barack Obama authorized the planting of cyber weapons in Russian infrastructure in the final weeks of his presidency in response to Moscow's interference in the 2016 presidential election. On 29 December 2016 United States imposed the most extensive sanctions against Russia since the Cold War, expelling 35 Russian diplomats from the United States. Economic sanctions are the most frequently used the foreign policy instruments by the United States today Thus, it is not surprising to see that economic sanctions are also used as counter policies against cyberattacks. According to Onder (2021), economic sanctions are also information gathering mechanisms for the sanctioning states about the capabilities of the sanctioned states. In March 2017, WikiLeaks published more than 8,000 documents on the CIA.
Successful bead beating is dependent not only on design features of the shaking machine (which take into consideration shaking oscillations frequency, shaking throw or distance, shaking orientation and vial orientation), but also the selection of correct bead size (0.1–6 mm (0.004–0.2 in) diameter), bead composition (glass, ceramic, steel) and bead load in the vial. In most laboratories, bead beating is done in batch sizes of one to twenty-four sealed, plastic vials or centrifuge tubes. The sample and tiny beads are agitated at about 2000 oscillations per minute in specially designed reciprocating shakers driven by high power electric motors. Cell disruption is complete in 1–3 minutes of shaking. Significantly faster rates of cell disruption are achieved with a bead beater variation called SoniBeast. Differing from conventional machines, it agitates the beads using a vortex motion at 20,000 oscillations per minute. Larger bead beater machines that hold deep-well microtiter plates also shorten process times, as do Bead Dispensers designed to quickly load beads into multiple vials or microplates. Pre-loaded vials and microplates are also available. All high energy bead beating machines warm the sample about 10 degrees per minute. This is due to frictional collisions of the beads during homogenization. Cooling of the sample during or after bead beating may be necessary to prevent damage to heat-sensitive proteins such as enzymes.
The Economic Times cited surveys showing "broad negative sentiment" about the economy, and Harris being "relentlessly hammered" by Trump during campaigns about this. The Economic Times cited University of Richmond School of Law professor Carl Tobias' appraisal of Trump's stance on immigration winning over Harris', and mentioned how Trump had increased his support from Hispanics, especially near the Mexican–American border and in areas impacted by recent immigration. Harris campaigning at multiple events with former Republican representative Liz Cheney has been suggested as a contributing factor as to why she lost. Los Angeles Times's Noah Bierman felt Harris could not overcome being the "turn the page" candidate, and cited former president Barack Obama's lead strategist David Axelrod, who said: "If you're the vice president of an administration people want to fire, you're way behind the eight-ball to start." Bierman wrote that besides criminal context, Trump "never followed a script, scoffed at the rules and spoke directly to the economic and cultural anxieties of the country". In The New York Times, Timothy Shenk argued that Democrats failed to articulate a vision for the future other than being against Trump and did not lean into a message of economic populism that polled best with swing voters, but also that the election looked more like a rejection of Biden than the embrace of Trump.
=== EC 1.17.1 With NAD or NADP as acceptor === EC 1.17.1.1: CDP-4-dehydro-6-deoxyglucose reductase EC 1.17.1.2: now classified as EC 1.17.7.4, 4-hydroxy-3-methylbut-2-enyl diphosphate reductase EC 1.17.1.3: leucoanthocyanidin reductase EC 1.17.1.4: xanthine dehydrogenase EC 1.17.1.5: nicotinate dehydrogenase EC 1.17.1.6: Now EC 1.17.99.5, bile-acid 7α-dehydroxylase. It is now known that FAD is the acceptor and not NAD+ as was thought previously EC 1.17.1.7: Now EC 1.2.1.91, 3-oxo-5,6-dehydrosuberyl-CoA semialdehyde dehydrogenase EC 1.17.1.8: 4-hydroxy-tetrahydrodipicolinate reductase EC 1.17.1.9: formate dehydrogenase EC 1.17.1.10: formate dehydrogenase (NADP+) EC 1.17.1.11: formate dehydrogenase (NAD+, ferredoxin)
Sources: en.wikipedia.org
The Bible may contain an early account of rhabdomyolysis. The Book of Numbers says that while traveling in the desert, people ate large quantities of quail meat, after which an illness killed numerous people. Rhabdomyolysis after consuming quail was described in more recent times and called coturnism (after Coturnix, the main quail genus). Migrating quail consume large amounts of hemlock, a known cause of rhabdomyolysis. In modern times, early reports from the 1908 Messina earthquake and World War I on kidney failure after injury were followed by studies by London physicians Eric Bywaters and Desmond Beall, working at the Royal Postgraduate Medical School and the National Institute for Medical Research, on four victims of the Blitz in 1941. Myoglobin was demonstrated in the urine of victims by spectroscopy, and it was noted that the kidneys of victims resembled those of patients who had hemoglobinuria (hemoglobin rather than myoglobin being the cause of the kidney damage). In 1944, Bywaters demonstrated experimentally that the kidney failure was mainly caused by myoglobin. Already during the war, teams of doctors traveled to bombed areas to provide medical support, chiefly with intravenous fluids, as dialysis was not yet available. The prognosis of acute kidney failure improved markedly when dialysis was added to supportive treatment, which first happened during the 1950–1953 Korean War.
The British policy as stated in the declaration was to face numerous challenges to its implementation in the following years. The first of these was the indirect peace negotiations which took place between Britain and the Ottomans in December 1917 and January 1918 during a pause in the hostilities for the rainy season; although these peace talks were unsuccessful, archival records suggest that key members of the War Cabinet may have been willing to permit leaving Palestine under nominal Turkish sovereignty as part of an overall deal. In October 1919, almost a year after the end of the war, Lord Curzon succeeded Balfour as Foreign Secretary. Curzon had been a member of the 1917 Cabinet that had approved the declaration, and according to British historian Sir David Gilmour, Curzon had been "the only senior figure in the British government at the time who foresaw that its policy would lead to decades of Arab–Jewish hostility". He therefore determined to pursue a policy in line with its "narrower and more prudent rather than the wider interpretation". Following Bonar Law's appointment as Prime Minister in late 1922, Curzon wrote to Law that he regarded the declaration as "the worst" of Britain's Middle East commitments and "a striking contradiction of our publicly declared principles". In August 1920 the report of the Palin Commission, the first in a long line of British Commissions of Inquiry on the question of Palestine during the Mandate period, noted that "The Balfour Declaration ... is undoubtedly the starting point of the whole trouble".
The functionality of a given protein is heavily dependent on its structure. Proteins reach this structure through the process of protein folding, which is facilitated by a variety of intra- and inter-molecular bonds. While much of the folding is driven by the formation of hydrogen bonds, covalent bonding of cysteine residues into disulfide bridges imposes constraints that stabilize particular conformations while preventing others from forming. As the bond energy of a covalent disulfide bridge is higher than the energy of a coordinate bond or hydrophobic interaction, greater numbers of disulfide bridges lead to higher energies required for protein denaturation. Disulfide bonds often serve to stabilize protein structures in the more oxidizing conditions of the extracellular environment. Within the cytoplasm, disulfide bonds may instead be reduced (i.e. in -SH form) to their constituent cysteine residues by thioredoxins. Many important cellular enzymes use prosthetic groups ending with sulfhydryl (-SH) moieties to handle reactions involving acyl-containing biochemicals: two common examples from basic metabolism are coenzyme A and alpha-lipoic acid. Cysteine-related metabolites homocysteine and taurine are other sulfur-containing amino acids that are similar in structure, but not coded by DNA, and are not part of the primary structure of proteins, take part in various locations of mammalian physiology. Two of the 13 classical vitamins, biotin and thiamine, contain sulfur, and serve as cofactors to several enzymes.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.